Welcome to our dedicated page for Biotricity news (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on Biotricity stock.
Biotricity Inc. (BTCY) delivers innovative medical technology solutions focused on AI-powered cardiac monitoring and chronic disease management. This news hub provides investors and healthcare professionals with essential updates on the company’s advancements in remote patient care.
Access timely press releases covering regulatory milestones, clinical study results, and strategic partnerships with healthcare institutions. Stay informed about product developments like the Bioflux cardiac monitoring system and consumer-focused Biolife platform, which combine medical-grade accuracy with AI-driven analytics.
Our curated news collection features earnings reports, technology patent announcements, and market expansion updates. Bookmark this page for verified information about BTCY’s progress in transforming cardiac care through connected health solutions.
Biotricity Inc. (NASDAQ:BTCY) reported its tenth consecutive quarter with triple-digit year-over-year revenue growth, achieving $1.81 million in Q2-FY22, a 143% increase compared to the prior year. The company incurred a net loss of $11 million, primarily due to $5.46 million in one-time expenses linked to its Nasdaq up-listing. Biotricity's balance sheet is robust, with $11.7 million in cash. The company introduced Biokit, a home-use cardiac monitoring device anticipated to launch in early 2022, indicating a strong product pipeline aimed at improving patient outcomes.
Biotricity, Inc. (BTCY) has announced the release of its financial results for the second quarter, ending September 30, 2021, scheduled for November 4, 2021, after market close. The company will host a conference call and live webcast at 2:00 PM PT (5:00 PM ET) on the same day to discuss the results. Biotricity focuses on remote health monitoring solutions, aiming to enhance preventive and personal care for chronic conditions.
Biotricity, Inc. (NASDAQ:BTCY) will present at the Virtual LD Micro Main Event XIV on October 13, 2021, at 5:00 PM PT. CEO Waqaas Al Siddiq will discuss recent milestones, including the development of Biokit, a home-use health monitoring solution, and the Biocare Cardiac app for cardiovascular health. The event, a key convention for small-cap companies, aims to connect industry leaders with analysts and investors. Biotricity focuses on innovative remote health monitoring solutions, aiming to improve chronic care management.
Biotricity Inc. (NASDAQ:BTCY) announced the launch of Biocare Cardiac, a cardiac health app designed for individuals with cardiovascular disease, compatible with Samsung's Galaxy Watch4. This app enables continuous monitoring of heart health, collecting data on ECG, heart rate, and more, facilitating better patient-doctor interactions. Biotricity aims to empower cardiac patients by providing tools for daily health management, addressing a significant gap in cardiac care. The app complements Biotricity's existing healthcare solutions, reinforcing its position in remote monitoring.
Biotricity Inc. (NASDAQ:BTCY) will ring the Nasdaq Opening Bell on October 7, 2021, at 9:30 AM ET. The ceremony will be attended by Founder and CEO Waqaas Al Siddiq and the management team. Recent developments include a financing initiative to support sales expansion while minimizing dilution and maximizing shareholder value. Additionally, Biotricity has expanded its telehealth product portfolio, enhancing its market potential. The event can be viewed on the Nasdaq live stream, with a replay available on the company's investor relations website.
Biotricity Inc. (NASDAQ:BTCY) announced its CEO, Waqaas Al Siddiq, will present at the Benzinga Healthcare Small Cap Conference on September 30, 2021, at 12:15 p.m. ET. The presentation will cover the company's strategic outlook for 2022, recent developments, and new products, including the Biokit bundle of wireless cardiac data devices. Biotricity aims to expand its market share and enhance shareholder value through its technology leadership and product pipeline. A replay of the presentation will be accessible on the corporate website for 30 days.
Biotricity Inc. (NASDAQ:BTCY) announces the upcoming launch of its Biokit, a connected personal medical device kit designed to enhance home-based health monitoring. The device aims to tackle challenges faced with existing products, aligning with the $18.4 billion North American portable medical device market. CEO Dr. Waqaas Al-Siddiq will present the company's long-term strategy at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021. This initiative positions Biotricity as a key player in remote monitoring and chronic care management.
Biotricity Inc. (NASDAQ:BTCY) announces the launch of its new Biokit, a personal medical device kit comprising an FDA-cleared digital thermometer, pulse oximeter, and blood pressure cuff. The kit aims to enhance remote cardiac monitoring and will be available in Q1 2022. These devices integrate with Biotricity's ecosystem, allowing real-time data sharing between patients and physicians. This launch is expected to expand the company's addressable market in the $18.4 billion North American portable medical device sector, aligning with Biotricity's goal to support cardiac patients effectively.
Biotricity, Inc. (NASDAQ:BTCY) announced a successful underwritten public offering, resulting in total gross proceeds of approximately $16 million. The offering, which closed on August 30, 2021, saw the underwriter partially exercise its option to purchase 382,331 additional shares, increasing the total shares sold to 5,382,331. This offering aligns with an effective shelf registration statement. H.C. Wainwright & Co. managed the offering, and it is aimed at advancing Biotricity's healthcare technology solutions.
Biotricity, Inc. (NASDAQ:BTCY) announced continued sales growth driven by the FDA-approved Bioflux mobile cardiac telemetry device, achieving a 290% year-over-year revenue increase in FY22-1Q and approximately 49% sequential growth. The company recently completed a $15 million equity raise and listed on the Nasdaq. CEO Waqaas Al-Siddiq will present at the H.C. Wainwright 23rd Annual Global Investment Conference, available on-demand from September 13-15, 2021. The focus will be on sales expansion and product portfolio growth to enhance the total addressable market.
